Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2064]
News [3529]
Articles [160]
Editorials [3]
Conferences [127]
elearning [18]

Strategies to improve the tolerability of treatment in patients with multiple myeloma

Prof Michel Delforge - Catholic University, Leuven, Belgium
Strategies to improve the tolerability of treatment in patients with multiple myeloma ( Prof Michel Delforge - Catholic University, Leuven, Belgium )
13 Jul 2012

Emerging advances in multiple myeloma; expert roundtable at MM CTP 2012

Prof Thierry Facon - Centre Hospitalier Universitaire, France, Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands,
Emerging advances in multiple myeloma; expert roundtable at MM CTP 2012 ( Prof Thierry Facon - Centre Hospitalier Universitaire, France, Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands, )
13 Jul 2012

Best treatment for chronic lymphocytic leukaemia with 17p deletion

Prof Michael Keating - MD Anderson Cancer Center, Houston, USA
Best treatment for chronic lymphocytic leukaemia with 17p deletion ( Prof Michael Keating - MD Anderson Cancer Center, Houston, USA )
12 Jul 2012

The involvement of rare cancer patients in clinical research

Jan Geissler - Co-founder of CML Advocates Network
The involvement of rare cancer patients in clinical research ( Jan Geissler - Co-founder of CML Advocates Network )
12 Jul 2012

New drugs on the CML horizon; choosing the correct therapies

Jan Geissler - Co-founder of CML Advocates Network, Prof Giuseppe Saglio - University of Turin, Italy, Dr Delphine Rea - Saint Louis Hospital, France
New drugs on the CML horizon; choosing the correct therapies ( Jan Geissler - Co-founder of CML Advocates Network, Prof Giuseppe Saglio - University of Turin, Italy, Dr Delphine Rea - Saint Louis Hospital, France )
5 Jul 2012

The evolving landscape in the management of CML

Jan Geissler - Co-founder of CML Advocates Network, Prof Giuseppe Saglio - University of Turin, Italy, Dr Delphine Rea - Saint Louis Hospital, France
The evolving landscape in the management of CML ( Jan Geissler - Co-founder of CML Advocates Network, Prof Giuseppe Saglio - University of Turin, Italy, Dr Delphine Rea - Saint Louis Hospital, France )
5 Jul 2012

Maintenance therapy in multiple myeloma; the way forward

Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo - University Hospital of Torino, Italy, Dr Paul Richardson - Dana-Farber Cancer Institute, USA
Maintenance therapy in multiple myeloma; the way forward ( Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo - University Hospital of Torino, Italy, Dr Paul Richardson - Dana-Farber Cancer Institute, USA )
4 Jul 2012

A new treatment paradigm in multiple myeloma

Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo - University Hospital of Torino, Italy, Dr Paul Richardson - Dana-Farber Cancer Institute, USA
A new treatment paradigm in multiple myeloma ( Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo - University Hospital of Torino, Italy, Dr Paul Richardson - Dana-Farber Cancer Institute, USA )
4 Jul 2012

Advances with bendamustine in multiple myeloma from EHA 2012

Prof Philippe Rodon - General Hospital, Blois, France
Advances with bendamustine in multiple myeloma from EHA 2012 ( Prof Philippe Rodon - General Hospital, Blois, France )
4 Jul 2012

Advances in multiple myeloma from EHA 2012

Prof Meletios Dimopoulos - Univeristy of Athens, Greece
Advances in multiple myeloma from EHA 2012 ( Prof Meletios Dimopoulos - Univeristy of Athens, Greece )
4 Jul 2012

Advances in multiple myeloma from EHA 2012; bortezomib and beyond

Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria
Advances in multiple myeloma from EHA 2012; bortezomib and beyond ( Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria )
4 Jul 2012

Dasatinib vs. imatinib first-line in CML; new study data

Prof Giuseppe Saglio - University of Turin, Italy
Dasatinib vs. imatinib first-line in CML; new study data ( Prof Giuseppe Saglio - University of Turin, Italy )
4 Jul 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation